OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Core Insights - OXB has been awarded the 'Most Innovative CDMO (Cell & Gene Therapy)' at the CDMO Leadership Awards in New York City, highlighting its leadership and innovation in the CDMO industry [1][2] - This recognition follows OXB's previous accolades, including a win in the 'Cell & Gene Therapy – Global' category in 2025 and being named a Champion in the 'Cell & Gene Therapy' category at the CDMO Leadership Awards Europe [2] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver life-changing therapies worldwide [4][5] - The company has 30 years of experience in viral vectors, which are essential for most cell and gene therapies, and collaborates with leading pharmaceutical and biotechnology companies [5] - OXB's capabilities span from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [5] Technological Capabilities - OXB offers a wide range of technologies for viral vector manufacturing, including the 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6] - The company employs advanced processes such as suspension and perfusion using process enhancers, along with stable producer and packaging cell lines [6] Facilities and Presence - OXB is headquartered in Oxford, UK, with development and manufacturing facilities located in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford MA and Durham NC, US [7]